Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors

Interleukin‐6 (IL‐6) may play a pathological role in rheumatoid arthritis (RA) and periodontitis. Although the efficacy of medication with IL‐6 receptor inhibitor, tocilizumab (TCZ), has been demonstrated in the treatment of RA, very little is known about whether TCZ therapy affects periodontitis. T...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Exp Dent Res
Main Authors: Kobayashi, Tetsuo, Ito, Satoshi, Kobayashi, Daisuke, Kojima, Anri, Shimada, Atsushi, Narita, Ichiei, Murasawa, Akira, Nakazono, Kiyoshi, Yoshie, Hiromasa
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2015
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839195/
https://ncbi.nlm.nih.gov/pubmed/29744142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cre2.11
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares